SCA
CELZ icon

Sassicaia Capital Advisers’s Creative Medical Technology CELZ Stock Holding History

Sassicaia Capital Advisers’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,120
Closed -$122K – 18
2022
Q1 		$122K Buy
+3,120
New +$69.4K 0.6% 18

Other funds holding CELZ

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sassicaia Capital Advisers's CELZ Position: Q2 2022 in Review

Sassicaia Capital Advisers sold out of Creative Medical Technology (CELZ) in Q2 2022, closing a stake of 3,120 shares — an estimated $122K sold.

Sassicaia Capital Advisers first reported a position in CELZ in Q1 2022 and held it in 1 quarter. The position peaked at $122K in Q1 2022. 14 funds tracked by Wall St. Rank hold CELZ as of Q2 2022.

  • Sassicaia Capital Advisers reported no remaining Creative Medical Technology position as of Q2 2022 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 3,120 Creative Medical Technology shares in Q2 2022, an estimated $122K.
  • Sassicaia Capital Advisers first reported a position in Creative Medical Technology in Q1 2022 and held it in 1 quarter.
  • Sassicaia Capital Advisers's Creative Medical Technology position peaked at $122K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2022.

Based on Sassicaia Capital Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.